Physician profile
Muhammad Raza
NPI 1669422119
$2,474.00
in general payments reported to CMS, 2019-2025
27 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.50 · 2021: $218 · 2022: $467 · 2023: $527 · 2024: $462 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $258.59 | 2022-2025 | |
| Insmed, INC. | $245.23 | 2023-2025 | Arikayce |
| Genzyme Corporation | $230.93 | 2021-2025 | |
| Pulmonx Corporation | $223.45 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Electromed, INC. | $216.92 | 2021-2025 | Smartvest |
| Steris Corporation | $158.48 | 2025 | |
| Penumbra, INC. | $149.87 | 2024 | Indigo System |
| Baxter Healthcare | $130.80 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Inspire Medical Systems, INC. | $106.34 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $100.48 | 2021-2023 | Fasenra, Breztri |
| Harmony Biosciences LLC | $85.29 | 2022-2024 | Wakix |
| Mylan Specialty L.P. | $77.05 | 2022-2024 | Yupelri |
| Boston Scientific Corporation | $66.19 | 2023 | Exalt Model D |
| Glaxosmithkline, LLC. | $62.57 | 2022-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.53 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $50.12 | 2021-2022 | |
| Philips North America LLC | $32.22 | 2022-2023 | |
| Fisher & Paykel Healthcare INC | $31.03 | 2024 | Fisher & Paykel Healthcare |
| Abiomed | $29.52 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.28 | 2021 | |
| Merck Sharp & Dohme LLC | $26.23 | 2023 | |
| Medtronic Vascular, INC. | $21.50 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $20.66 | 2023 | Opsumit, Uptravi |
| Gilead Sciences, INC. | $18.84 | 2022 | |
| Abbvie INC. | $15.95 | 2023 | |
| Apria Healthcare LLC | $13.54 | 2021 | |
| Olympus America INC. | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.